Real-world evaluation of epidemiology, treatment environment and bone fracture risk associated with glucocorticoid-induced osteoporosis in Japa
Not Applicable
- Conditions
- Glucocorticoid-induced osteoporosis (GIOP)
- Registration Number
- JPRN-UMIN000041498
- Lead Sponsor
- DAIICHI SANKYO CO., LTD.
- Brief Summary
The fracture rate (all sites) at one year after steroid prescriptions was 9.3% [95% CI: 8.8-9.8] in steroid-exposed group and 5.8% [5.4-6.2] in steroid-unexposed group. The fracture rate was higher in steroid-exposed group compared to steroid-unexposed group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25569
Inclusion Criteria
Not provided
Exclusion Criteria
Having been diagnosed with any endocrine disease of interest which associated with reduced bone density
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways contribute to glucocorticoid-induced osteoporosis (GIOP) in Japanese populations?
How does real-world GIOP management in Japan compare to standard-of-care bisphosphonate or denosumab therapies globally?
Which biomarkers correlate with fracture risk in glucocorticoid-exposed patients with GIOP?
What adverse events are associated with long-term glucocorticoid use in GIOP patients, and how are they managed?
How do RANKL inhibitors or SERMs compare to current GIOP treatment strategies in reducing fracture incidence?